News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Cuts Reps Before Lipitor Patent Expires


8/15/2011 7:33:17 AM

This should not come as a surprise. The big drugmaker just two months ago disclosed plans to cut another $1 billion or so in expenses, with a first phase that will amount to $500 million in cutbacks taking place this year. The move, of course, comes in response to the loss of patent protection for the Lipitor cholesterol pill, a $10.7 billion seller, and other big-selling meds. Pfizer sales reps were told to expect phone calls next week about their fate. Some say, however, there is frustration in the ranks. The drugmaker has allegedly indicated more than once that the sales force was “told since the Wyeth acquisition that Pfizer was “right sized” ‘ for the Lipitor patent expiration that will occur this fall, one source tells us.

Read at Pharmalot

comments powered by Disqus
Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES